Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhCOL3 in breast tumor surgery
NCT06725082Phase 1Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of recombinant human type III collagen in breast cancer (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Short-term postoperative complications after surgery and radiotherapy at 3 months. Started Dec 2024; status: recruiting.
02
Drugs
recombinant human type III collagen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06725082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06725082.